Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Champions Oncology (CSBR) Competitors

Champions Oncology logo

CSBR vs. TRML, ORKA, SVRA, RIGL, HRTX, AQST, NKTR, CBIO, ALT, and NATR

Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Tourmaline Bio (TRML), Oruka Therapeutics (ORKA), Savara (SVRA), Rigel Pharmaceuticals (RIGL), Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST), Nektar Therapeutics (NKTR), Crescent Biopharma (CBIO), Altimmune (ALT), and Nature's Sunshine Products (NATR). These companies are all part of the "med - drugs" industry.

Champions Oncology vs. Its Competitors

Champions Oncology (NASDAQ:CSBR) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

In the previous week, Champions Oncology had 21 more articles in the media than Tourmaline Bio. MarketBeat recorded 22 mentions for Champions Oncology and 1 mentions for Tourmaline Bio. Champions Oncology's average media sentiment score of 1.04 beat Tourmaline Bio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Champions Oncology
15 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Tourmaline Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Champions Oncology currently has a consensus price target of $12.00, suggesting a potential upside of 42.69%. Tourmaline Bio has a consensus price target of $49.33, suggesting a potential upside of 203.03%. Given Tourmaline Bio's higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Champions Oncology
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Champions Oncology has a net margin of 10.97% compared to Tourmaline Bio's net margin of 0.00%. Champions Oncology's return on equity of 656.65% beat Tourmaline Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Champions Oncology10.97% 656.65% 24.04%
Tourmaline Bio N/A -26.75%-26.11%

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Champions Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Champions Oncology has higher revenue and earnings than Tourmaline Bio. Champions Oncology is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$50.15M2.32-$7.28M-$0.06-140.14
Tourmaline BioN/AN/A-$73.21M-$3.21-5.07

Summary

Champions Oncology beats Tourmaline Bio on 10 of the 14 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSBR vs. The Competition

MetricChampions OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$122.92M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E Ratio19.118.9827.0020.10
Price / Sales2.32729.50428.95120.24
Price / CashN/A159.8036.8257.86
Price / Book-60.074.517.985.56
Net Income-$7.28M$31.26M$3.16B$248.40M

Champions Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSBR
Champions Oncology
4.3996 of 5 stars
$8.41
-13.0%
$12.00
+42.7%
+70.9%$122.92M$50.15M19.11143News Coverage
Positive News
TRML
Tourmaline Bio
2.1096 of 5 stars
$15.99
-3.3%
$49.33
+208.5%
+22.4%$424.84MN/A-4.9844
ORKA
Oruka Therapeutics
2.5987 of 5 stars
$11.21
+1.2%
$40.38
+260.2%
N/A$414.84MN/A-2.49N/A
SVRA
Savara
2.2058 of 5 stars
$2.28
+3.2%
$5.60
+145.6%
-50.3%$381.97MN/A-4.75N/APositive News
High Trading Volume
RIGL
Rigel Pharmaceuticals
2.3944 of 5 stars
$18.73
-3.9%
$36.40
+94.3%
+134.1%$348.15M$179.28M9.05160
HRTX
Heron Therapeutics
3.8245 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-25.9%$326.49M$144.29M-34.50300Positive News
AQST
Aquestive Therapeutics
1.244 of 5 stars
$3.31
+1.8%
$10.14
+206.4%
+53.3%$322.82M$57.56M-5.61160
NKTR
Nektar Therapeutics
4.8142 of 5 stars
$25.84
+0.3%
$84.17
+225.7%
+22.2%$319.60M$98.43M-2.69220Analyst Forecast
High Trading Volume
CBIO
Crescent Biopharma
3.2611 of 5 stars
$16.14
+1.5%
$25.00
+54.9%
N/A$310.84M$10K-0.3526News Coverage
Gap Up
ALT
Altimmune
2.2151 of 5 stars
$3.87
+10.6%
$19.00
+391.0%
-33.5%$283.87M$20K-3.0750High Trading Volume
NATR
Nature's Sunshine Products
1.8586 of 5 stars
$14.79
+2.0%
$18.33
+24.0%
+5.5%$267.72M$454.36M27.91850High Trading Volume

Related Companies and Tools


This page (NASDAQ:CSBR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners